Qiagen (NYSE:QGEN) and Oncotelic Therapeutics (OTCMKTS:OTLC) Head to Head Survey

Oncotelic Therapeutics (OTCMKTS:OTLC) and Qiagen (NYSE:QGEN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

Profitability

This table compares Oncotelic Therapeutics and Qiagen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncotelic Therapeutics	N/A	183.45%	117.54%
Qiagen	19.16%	14.40%	8.40%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Oncotelic Therapeutics and Qiagen, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncotelic Therapeutics	0	0	0	0	0.00
Qiagen	1	7	4	1	2.38

Qiagen has a consensus price target of $43.15, indicating a potential upside of 7.65%. Given Qiagen’s stronger consensus rating and higher possible upside, analysts clearly believe Qiagen is more favorable than Oncotelic Therapeutics.

Earnings and Valuation

This table compares Oncotelic Therapeutics and Qiagen”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncotelic Therapeutics	$70,000.00	266.79	$249.28 million	$0.59	0.07
Qiagen	$2.09 billion	3.95	$424.88 million	$1.91	20.98

Qiagen has higher revenue and earnings than Oncotelic Therapeutics. Oncotelic Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

70.0% of Qiagen shares are owned by institutional investors. 39.2% of Oncotelic Therapeutics shares are owned by insiders. Comparatively, 9.0% of Qiagen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Oncotelic Therapeutics has a beta of -0.27, meaning that its stock price is 127% less volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500.

Summary

Qiagen beats Oncotelic Therapeutics on 11 of the 15 factors compared between the two stocks.

About Oncotelic Therapeutics

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of Artemisinin based products and support technologies. Oncotelic Therapeutics, Inc. is based in Agoura Hills, California.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.